Skip to content

CAMBRIDGE, Mass., March 24, 2015 /PRNewswire/ -- Pronutria Biosciences™ Inc., a biotechnology company developing a new class of therapeutics to mediate amino acid biology, announced today the appointment of Dr. Christopher Wright as Senior Vice President and Chief Medical Officer. Dr. Wright will lead the company's global clinical development and medical affairs.

Dr. Wright has over 15 years of experience in academic medicine and biopharmaceuticals. Prior to joining Pronutria Biosciences, Dr. Wright was Senior Vice President and Head of Global Medicine Development and Affairs at Vertex Pharmaceuticals, Inc., where he led global development functions across all therapeutic areas of clinical development, medical affairs, clinical operations, medical writing, biometrics, regulatory affairs and patient safety. He directly oversaw the successful submission of KALYDECO® for approval to the FDA, EMA and other drug approval entities in Europe, Canada and Australia. Prior to this, Dr. Wright served as Vice President of Clinical Development at Vertex Pharmaceuticals, where he oversaw clinical programs in the areas of hepatitis C, cystic fibrosis, epilepsy, rheumatoid arthritis, influenza and pain.

"I look forward to joining the outstanding team of scientists at Pronutria Biosciences," said Dr. Wright. "Using highly innovative, precision-based approaches to restore amino acid balance offers us the opportunity to impact the lives of patients and families confronting debilitating diseases."

Dr. Wright is a practicing neurologist at Brigham and Women's Hospital. Previously, Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and a Harvard-MIT Clinical Investigator Training Program graduate and advisor. He received his Bachelor's in Biochemical Sciences from Harvard University, his M.D. and MMSc. from Harvard Medical School and his Ph.D. from Vrije University in the Netherlands. Dr Wright has received numerous awards and grants including from the National Institutes of Health (NIH), the Robert Wood Johnson Foundation, the National Alliance for Research in Schizophrenia and Depression (NARSAD) and the Human Frontier Science Program Organization (HFSPO).

"Chris is a prominent and accomplished scientific and medical leader in both the academic and biopharmaceutical communities," said Dr. Peter Mueller, President of Research and Development and Chief Scientific Officer, Pronutria Biosciences. "His outstanding dedication to patients and proven track record in translating frontier science into breakthrough therapeutic regimens make him the ideal choice to lead the clinical development of our novel treatment modality that can have enormous impacts on global health."

About Pronutria Biosciences

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated. Pronutria Biosciences is developing first-in-class solutions to these conditions with a focus on amino acid biology. Using insights from a clinically validated body of evidence, we are pioneering new nutritional and therapeutic modalities: amino acid biologics. This novel approach allows us to precisely target biology that was previously inaccessible, providing a unique opportunity to address a variety of serious diseases and medical conditions, such as metabolic disorders, neurodegenerative diseases and critical care conditions, using nutritional and therapeutic approaches. For more information, please visit